Mostrar el registro sencillo del ítem
dc.contributor.author | Maco, V. | |
dc.contributor.author | Marcos, L. | |
dc.contributor.author | Delgado, J. | |
dc.contributor.author | Herrera, J. | |
dc.contributor.author | Nestares, J. | |
dc.contributor.author | Terashima, A. | |
dc.contributor.author | Samalvides Cuba, Frine | |
dc.contributor.author | Gotuzzo Herencia, José Eduardo | |
dc.date.accessioned | 2019-04-24T18:23:57Z | |
dc.date.available | 2019-04-24T18:23:57Z | |
dc.date.issued | 2015 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12866/6495 | |
dc.description.abstract | Introduction: The therapeutic scheme of triclabendazole (TCBZ), the recommended anthelmintic against Fasciola hepatica, involves 10mg/kg of body weight administered in a single dose; however, clinical trials in children are scarce. We evaluated the efficacy and tolerability of 2 schemes of TCBZ. Methods: Eighty-four Peruvian children with F. hepatica eggs in their stools were allocated into 2 groups: 44 received 2 dosages of 7.5mg/kg each with a 12-h interval (Group I), and 40 received a single 10-mg/kg dose (Group II). Evaluation of efficacy was based on the presence of eggs in stools, and tolerability was based on the presence of symptoms and signs post-treatment. Results: A parasitological cure was obtained in 100% of individuals from Group I and 95% of individuals from Group II. The most common adverse event was biliary colic. Conclusions: The tested scheme was efficacious and tolerable, and it might be an optimal scheme in the region. To the best of our knowledge, this represents the largest series of children treated with TCBZ in a non-hospital setting. | en_US |
dc.language.iso | eng | |
dc.publisher | Sociedade Brasileira de Medicina Tropical | |
dc.relation.ispartofseries | Revista da Sociedade Brasileira de Medicina Tropical | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.subject | triclabendazole | en_US |
dc.subject | anthelmintic agent | en_US |
dc.subject | benzimidazole derivative | en_US |
dc.subject | triclabendazole | en_US |
dc.subject | abdominal pain | en_US |
dc.subject | anorexia | en_US |
dc.subject | Article | en_US |
dc.subject | biliary colic | en_US |
dc.subject | child | en_US |
dc.subject | controlled study | en_US |
dc.subject | drug efficacy | en_US |
dc.subject | enzyme linked immunosorbent assay | en_US |
dc.subject | epigastric pain | en_US |
dc.subject | Fasciola hepatica | en_US |
dc.subject | fascioliasis | en_US |
dc.subject | feces analysis | en_US |
dc.subject | female | en_US |
dc.subject | headache | en_US |
dc.subject | human | en_US |
dc.subject | major clinical study | en_US |
dc.subject | male | en_US |
dc.subject | multicenter study | en_US |
dc.subject | nausea and vomiting | en_US |
dc.subject | nonhuman | en_US |
dc.subject | Peru | en_US |
dc.subject | phase 2 clinical trial | en_US |
dc.subject | single drug dose | en_US |
dc.subject | treatment outcome | en_US |
dc.subject | adolescent | en_US |
dc.subject | animal | en_US |
dc.subject | clinical protocol | en_US |
dc.subject | clinical trial | en_US |
dc.subject | drug administration | en_US |
dc.subject | fascioliasis | en_US |
dc.subject | feces | en_US |
dc.subject | parasite identification | en_US |
dc.subject | parasitology | en_US |
dc.subject | preschool child | en_US |
dc.subject | severity of illness index | en_US |
dc.subject | Fasciola hepatica | en_US |
dc.subject | Adolescent | en_US |
dc.subject | Animals | en_US |
dc.subject | Anthelmintics | en_US |
dc.subject | Benzimidazoles | en_US |
dc.subject | Child | en_US |
dc.subject | Child, Preschool | en_US |
dc.subject | Clinical Protocols | en_US |
dc.subject | Drug Administration Schedule | en_US |
dc.subject | Fasciola hepatica | en_US |
dc.subject | Fascioliasis | en_US |
dc.subject | Feces | en_US |
dc.subject | Female | en_US |
dc.subject | Humans | en_US |
dc.subject | Male | en_US |
dc.subject | Parasite Egg Count | en_US |
dc.subject | Peru | en_US |
dc.subject | Severity of Illness Index | en_US |
dc.title | Efficacy and tolerability of two single-day regimens of triclabendazole for fascioliasis in Peruvian children | en_US |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | https://doi.org/10.1590/0037-8682-0148-2015 | |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.03.06 | |
dc.relation.issn | 1678-9849 |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |